Joyce O’Shaughnessy, MD

home / authors / joyce-o-shaughnessy-md

Articles

August 12th 2024

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

August 5th 2024

Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.

August 5th 2024

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

July 29th 2024

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

July 29th 2024

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.

July 29th 2024

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A medical expert navigates toxicity management in patients being treated with ribociclib.

July 29th 2024

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. Rugo details her management strategy in regards to GI toxicities.

July 10th 2024

Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.

July 10th 2024

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

Latest Updated Articles

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: December 12th 2013 | Updated: October 23rd 2024

Relying on ACOs and TCOC Contracting to 'Bend the Cost Curve'

Published: March 18th 2014 | Updated: October 23rd 2024

It's Time to Embolden the Nation's Experiments With ACOs

Published: July 16th 2013 | Updated: October 23rd 2024

Healthcare's 'Big Data' Challenge

Published: July 10th 2013 | Updated: October 23rd 2024

Early Results From the Hospital Electronic Health Record Incentive Programs

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions